Skip to Main Content

Author Details

Jihye Park
Dana-Farber Cancer Institute, Harvard Medical School
2015
33
21
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36712083Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.medRxiv2023
36712083Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.medRxiv2023
37301199HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery.Immunity2023
37301199HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery.Immunity2023
34986355Integrative clinical and molecular characterization of translocation renal cell carcinoma.Cell Rep2022
35464471Deconvolution of Adult T-Cell Leukemia/Lymphoma With Single-Cell RNA-Seq Using Frozen Archived Skin Tissue Reveals New Subset of Cancer-Associated Fibroblast.Front Immunol2022
36075011Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.JCO Precis Oncol2022
34986355Integrative clinical and molecular characterization of translocation renal cell carcinoma.Cell Rep2022
35464471Deconvolution of Adult T-Cell Leukemia/Lymphoma With Single-Cell RNA-Seq Using Frozen Archived Skin Tissue Reveals New Subset of Cancer-Associated Fibroblast.Front Immunol2022
36075011Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.JCO Precis Oncol2022
34120146Metabolic alterations mediated by STAT3 promotes drug persistence in CML.Leukemia2021
34120146Metabolic alterations mediated by STAT3 promotes drug persistence in CML.Leukemia2021
34099491Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival.Cancer Res2021
33711272Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.Cancer Cell2021
33547292Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun2021
34552244Biologically informed deep neural network for prostate cancer discovery.Nature2021
34496240Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.Cell Rep2021
34548479Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Nat Commun2021
35121878Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.Nat Cancer2021
33547292Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nat Commun2021
33711272Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.Cancer Cell2021
35121878Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology.Nat Cancer2021
34552244Biologically informed deep neural network for prostate cancer discovery.Nature2021
34496240Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.Cell Rep2021
34548479Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Nat Commun2021
34099491Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival.Cancer Res2021
32127357<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.Cancer Res2020
32127357<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.Cancer Res2020
32442065Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.J Clin Oncol2020
32542325Lysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance.Blood2020
32533060Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.Nat Commun2020
33409501Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.Nat Cancer2020
33409501Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.Nat Cancer2020
32442065Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.J Clin Oncol2020
32542325Lysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance.Blood2020
32533060Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.Nat Commun2020
30026571Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.Leukemia2019
30026571Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.Leukemia2019
29703982Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Nat Commun2018
29925904Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.Leukemia2018
30274786RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.Mol Ther2018
29440174Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.Clin Cancer Res2018
29703982Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Nat Commun2018
29558366Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.J Clin Invest2018
29925904Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.Leukemia2018
30274786RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.Mol Ther2018
29440174Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation.Clin Cancer Res2018
29558366Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.J Clin Invest2018
27531699Genomic complexity of multiple myeloma and its clinical implications.Nat Rev Clin Oncol2017
28344315Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.Leukemia2017
  • 1 - 50 of 66

Recommended Authors

Susanne Beck
Vrije Universiteit Brussel (VUB)
Career Start Year 2018
Number of shared co-authors 0
Giulia Biancon
Yale School of Medicine
Career Start Year 2016
Number of shared co-authors 1
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 0
Reyka G Jayasinghe
Washington University in St Louis
Career Start Year 2015
Number of shared co-authors 0
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 5
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Alex Murison
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2012
Number of shared co-authors 3
Benjamin G Barwick
Emory University School of Medicine
Career Start Year 2009
Number of shared co-authors 3
Christopher A Miller
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 1
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 2
Catrina Fronick
McDonnell Genome Institute, Washington University in St. Louis School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 10
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Malachi Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 0
Fei Yang
Oregon Health & Science University
Career Start Year 2002
Number of shared co-authors 0
Arun P Wiita
University of California San Francisco
Career Start Year 2002
Number of shared co-authors 1
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 7
Ludmila Danilova
Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine
Career Start Year 2001
Number of shared co-authors 4
Jacqueline E Payton
Washington University School of Medicine.
Career Start Year 2001
Number of shared co-authors 1
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year 1999
Number of shared co-authors 3
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 5
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 4
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 4
James J Hsieh
Washington University
Career Start Year 1994
Number of shared co-authors 8
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 4

Collaborators

Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 15
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 6
Jake Conway
Co-authored papers 5
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 4
Daniel G Tenen
Harvard Stem Cell Institute, Harvard Medical School
Co-authored papers 3
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 3
Robert S Welner
University of Alabama at Birmingham
Co-authored papers 3
Ignaty Leshchiner
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 2
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 2
Samuel S Freeman
St Vincent's Hospital Melbourne
Co-authored papers 2
Chip Stewart
Broad Institute of MIT and Harvard
Co-authored papers 2
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 2
Karl R Clauser
Co-authored papers 2
Catherine J Wu
Co-authored papers 2
Peter Leif Bergsagel
Co-authored papers 2
Jonathan J Keats
Co-authored papers 1
Nancy U Lin
Co-authored papers 1
Virginia Camacho
Boston Children's Hospital, Harvard Medical School
Co-authored papers 1
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 1
Henry Yang
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 1
Rui Lu
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
Victoria R Matkins
O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham
Co-authored papers 1
Rosina T Lis
National Cancer Institute
Co-authored papers 1
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 1
Zongliang Yue
University of Alabama at Birmingham, USA Informatics Institute
Co-authored papers 1
Brian J Haas
Broad Institute of MIT and Harvard
Co-authored papers 1
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 1
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 1
Myles Brown
Co-authored papers 1
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 1
Release 1.2